Genmab Bispecific Deal History & Licensing Activity
Genmab Bispecific is a large biotech headquartered in Denmark. Over the past three years, Genmab Bispecific has been involved in 2 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (3 deals).
Deals (12mo)
1
Active Trials
20
Top Modality
Bispecific Antibodies
Focus Area
Oncology
Genmab Bispecific Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Genmab Bispecific in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| petosemtamab | Genmab A/S | Bispecific Antibodies | Phase 3 | acquisition | Sep 29, 2025 |
Genmab Bispecific Pipeline Focus
Therapeutic areas and modalities where Genmab Bispecific is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Genmab Bispecific Strategic Signals
Key indicators of Genmab Bispecific's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Genmab Bispecific's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Genmab Bispecific Licensing & Deal Activity
Genmab Bispecific is a large biotech company based in Denmark that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Genmab Bispecific ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genmab Bispecific include Oncology (3 deals and trials). In terms of modality, Genmab Bispecific has shown particular interest in bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genmab Bispecific and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Genmab Bispecific's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.